The Invesco Dynamic Pharmaceuticals ETF includes 30 US pharmaceutical stocks that are principally engaged in the research, development, manufacturing, distribution, or sale of pharmaceuticals and drugs of all kinds. Invesco Dynamic Pharmaceuticals ETF is a fund that is based on the Dynamic Pharmaceutical Intellidex℠ Index, which is designed to provide capital appreciation by thoroughly evaluating companies based on price momentum, quality, earnings momentum, management action, and value. Invesco Dynamic Pharmaceuticals ETF (PJP) Those securities are then ranked and weighed according to volatility, value, and growth as FTXH seeks to replicate the holdings and weightings of the Nasdaq US Smart Pharmaceuticals Index in order to generate performance results 95% correlated to that index. FTXH chooses 30 of the most liquid pharmaceutical stocks in the US, based on average daily traded volume over three months. While many funds perform a basic liquidity screen as part of their index construction and rebalancing, FTXH goes beyond the basic screen and uses liquidity selection. The First Trust NASDAQ Pharmaceutical ETF tracks highly liquid pharmaceutical stocks that are weighted according to different factors. First Trust NASDAQ Pharmaceuticals ETF (FTXH) Here are some of the pharmaceutical ETFs to consider: 1.

Pharmaceutical ETFs also give investors a broad view of what these pharma companies have to offer and where they stand in the market. The company is getting close to bringing its NanoFlu vaccine to market after announcing positive results for Phase II of its clinical trials in older adults in January. Then there is Novavax (NASDAQ:NVAX), a vaccine developer that is focused on the prevention of diseases from the Zika virus to the seasonal flu. > RVLV Stock Jumps 89% on First Day of Trading on NYSE: IPO Success The company has one drug that has already been FDA approved and was commercialized by Roche (OTCQX:RHHBF) and Genentech. Curis conducts a significant amount of research and works with other drugs makers in testing and developing drugs. (NASDAQ:CRIS) is another company that is focused on developing drugs that treat cancers. Telomerase is an enzyme that enables cancer cells to multiply, and Geron’s imetelstat is designed to stop telomerase activity and impeding malignant cell proliferation.Ĭuris Inc. One of these is Geron Corporation (NASDAQ:GERN), which has developed a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. However, there are a number of small-cap pharmaceutical stocks that are developing revolutionary new treatments that have massive potential.

The pharmaceutical market is currently dominated by massive drug companies like Johnson & Johnson (NYSE:JNJ), which brought in a whopping $81.58 billion in revenue in 2018, and Pfizer (NYSE:PFE), which reported $53.6 billion in revenue for 2018. The other top therapy areas include anti-diabetics, anti-rheumatics, vaccines, and anti-virals. In fact, oncology therapy was worth $107 billion in sales in 2017 and is expected to grow at a 12.2% compound annual growth rate (CAGR) to $233 billion by 2024. Leading the way will be pharmaceutical stocks that are focused on cancer treatments, which has been by far the largest area of focus in the pharmaceutical world. Some of the factors behind the market’s growth include the aging population, lifestyle diseases, FDA approvals, and healthcare legislation. The global pharmaceutical market has been growing at a rapid rate in recent years and is expected to reach $1.57 trillion USD by 2023, signaling a major opportunity for investors to cash in on pharmaceutical stocks.

Investing in micro cap stocks